Newron Pharmaceuticals S.p.A.
OTC: NWPHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stefan Weber
- Employees
- 22
- Headquarters
- Bresso, Italy
- IPO year
- 2017
- Market cap
- $416.1M
- Website
- https://www.newron.com
Loading NWPHF…
Loading profile data…Frequently asked questions about NWPHF
What does Newron Pharmaceuticals S.p.A. (NWPHF) do?
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions. Operating in both Italy and the United States, the company's portfolio includes Xadago (safinamide), an a...
Where does NWPHF trade?
Newron Pharmaceuticals S.p.A. (NWPHF) trades on the Other OTC.
What sector is NWPHF in?
Newron Pharmaceuticals S.p.A. (NWPHF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Newron Pharmaceuticals S.p.A.?
Stefan Weber is the chief executive officer of Newron Pharmaceuticals S.p.A. (NWPHF).
Where is Newron Pharmaceuticals S.p.A. headquartered?
Newron Pharmaceuticals S.p.A. is headquartered in Italy.
Does NWPHF pay a dividend?
Newron Pharmaceuticals S.p.A. (NWPHF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NWPHF go public?
Newron Pharmaceuticals S.p.A. (NWPHF) completed its initial public offering in 2017.